Home›Trial›NCT07205159
NCT07205159Phase 1RECRUITING

A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Severe to Very Severe Alopecia Areata.

Study Summary

This is a randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of FB102 in patients with severe to very severe alopecia areata (AA).

Conditions
Alopecia Areata
Interventions / Drugs
FB102Placebo
View on ClinicalTrials.gov ↗
Sponsor
FBRX
Forte Biosciences
Dermatology
D39/100
Study Details
Enrollment32 participants
Primary Completion—
Lead SponsorForte Biosciences, Inc.
Data Retrieved2026-04-11 04:13:59.421351+00:00
What This Trial Means for Biotech Investors
Trial Phase Context

Phase 1 trials primarily test safety and dosing in a small number of participants (typically 20–100). Results do not yet speak to efficacy. FDA approval is typically many years away from this stage.

Status & Expected Data

Currently recruiting: the trial is enrolling patients. A data readout is not expected until after enrollment closes and the follow-up period is complete.

Enrolled: 32 participants
Sponsor Catalyst Profile

Forte Biosciences (FBRX) is the sponsoring company for this trial. BiotechSign currently grades this company D (39/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

FBRX Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.